drugset / Trial / NCT06964191

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension

NCT06964191

Phase 2 Active not recruiting 75 enrolled PolyActiva Pty Ltd IUVO S.r.l. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to the standard treatment therapy.

Timeline

Start
2025-05-31
Primary completion
2026-11-15
Completion
2026-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule Topical
Subject PA5108 Ocular Implant Unknown Other